Biguanide
Metformin for Prediabetes
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.
Air Filtration
Air Filtration for Heart Disease
This trial tests if using special air filters in homes can help people with heart disease by cleaning the air they breathe. The goal is to see if reducing indoor air pollution can slow down the worsening of their heart condition.
ACL-inhibiting Regimen
Bempedoic Acid for HIV-Related Cardiovascular Disease
This trial will study the effect of Bempedoic acid (BA) on safety, arterial inflammation, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in HIV-infected individuals aged ≥40 years with known CVD or 1 CVD risk factor.
Popular Filters
Trials for Peripheral Arterial Disease Patients
Microbiome Therapy
Fecal Microbial Transplant for Atherosclerosis
"This trial aims to treat patients with unexplained severe atherosclerosis by giving them fecal transplants from patients with a Protected phenotype. The goal is to see how this affects the intestinal microbiome and
Anti-inflammatory
Colchicine for Cardiovascular Disease in Diabetes
This trial tests colchicine to see if it can reduce inflammation in blood vessel plaques in high-risk patients with diabetes or pre-diabetes who recently had a heart attack or stroke. The goal is to prevent future cardiovascular events by reducing plaque inflammation. Colchicine is an ancient drug with anti-inflammatory effects, historically used for conditions like gout and familial Mediterranean fever, and has shown promise in reducing cardiovascular events by targeting inflammation in blood vessel plaques.
Tissue Selective Estrogen Complex
Bazedoxifene + Estrogens for Atherosclerosis
This trial is designed to test the effects of a tissue selective estrogen complex on the progression of subclinical atherosclerosis and cognitive decline in 360 postmenopausal women.
Trials for Peripheral Artery Disease Patients
Microbiome Therapy
Fecal Microbial Transplant for Atherosclerosis
"This trial aims to treat patients with unexplained severe atherosclerosis by giving them fecal transplants from patients with a Protected phenotype. The goal is to see how this affects the intestinal microbiome and
Anti-inflammatory
Colchicine for Cardiovascular Disease in Diabetes
This trial tests colchicine to see if it can reduce inflammation in blood vessel plaques in high-risk patients with diabetes or pre-diabetes who recently had a heart attack or stroke. The goal is to prevent future cardiovascular events by reducing plaque inflammation. Colchicine is an ancient drug with anti-inflammatory effects, historically used for conditions like gout and familial Mediterranean fever, and has shown promise in reducing cardiovascular events by targeting inflammation in blood vessel plaques.
Tissue Selective Estrogen Complex
Bazedoxifene + Estrogens for Atherosclerosis
This trial is designed to test the effects of a tissue selective estrogen complex on the progression of subclinical atherosclerosis and cognitive decline in 360 postmenopausal women.
Phase 3 Trials
Anti-inflammatory
Colchicine for Cardiovascular Disease in Diabetes
This trial tests colchicine to see if it can reduce inflammation in blood vessel plaques in high-risk patients with diabetes or pre-diabetes who recently had a heart attack or stroke. The goal is to prevent future cardiovascular events by reducing plaque inflammation. Colchicine is an ancient drug with anti-inflammatory effects, historically used for conditions like gout and familial Mediterranean fever, and has shown promise in reducing cardiovascular events by targeting inflammation in blood vessel plaques.
siRNA
Inclisiran for Cardiovascular Disease
This trial is testing inclisiran, an injectable drug, on people with heart disease who are already on strong cholesterol-lowering medications. The goal is to see if inclisiran can further reduce the risk of heart attacks and strokes by lowering bad cholesterol levels. Participants will receive the injection periodically. Inclisiran works by significantly reducing bad cholesterol levels.
RNA-based Therapeutic
Inclisiran for Cardiovascular Disease
This trial tests inclisiran, a new injection to lower cholesterol, in people who have had heart attacks, strokes, or surgeries for blocked arteries. It works by blocking a protein that produces bad cholesterol.
Monoclonal Antibodies
CSL300 for Kidney Failure
This trial is testing CSL300, a new treatment, to see if it helps people with heart disease or diabetes who are on dialysis. The study aims to find the right dose and check if it improves heart health by reducing inflammation.
Trials With No Placebo
Behavioural Intervention
Lifestyle Modification for Coronary Artery Disease
This trial is looking at whether a combined image-treatment regimen of PET + lifestyle modification and lipid-lowering drugs can improve cardiovascular risk score and potentially lower rate of death and other heart problems, compared to current standard of care.
View More Related Trials
Frequently Asked Questions
Introduction to atherosclerosis
What are the top hospitals conducting atherosclerosis research?
In the battle against atherosclerosis, several top hospitals across different locations are leading the charge in clinical trials aimed at understanding and combating this condition. Massachusetts General Hospital, situated in Boston, stands out with five ongoing trials focused on atherosclerosis. With a history of 19 trials dedicated to this artery-clogging disease, their commitment dates back to their first recorded trial in 2000. Meanwhile, on the West Coast, Westside Medical Associates of Los Angeles is making significant contributions as well. This Beverly Hills-based institution has four active atherosclerosis trials underway and has conducted five previous studies since initiating its first trial in 2016.
Moreover, Excel Medical Clinical Trials based in Boca Raton demonstrates its dedication through four ongoing clinical investigations into atherosclerosis since recording its inaugural trial on this subject matter as recently as 2021. Similarly enthusiastic about advancing knowledge and treatment options for those suffering from this ailment is Clinical Trials Research located in Lincoln; they contribute actively by conducting three current investigations while boasting three accomplished experiments initiated when they administered their initial record-trialing process regarding Atherosclerosis just last year -in2022.
Lastly,the efforts of West Broadway Clinic located specifically within Council Bluffs region also constitutes notable contribution towards broadening insights amidst fight against aforementioned ailment ;they undertake similar magnitude of task being involved with research pertaining towards three active clinical examinations targeting Atherosclerotic territories.These relatively smaller-scale institutions hold equal importance given that every step taken toward comprehending and managing Atherosclerosis ultimately offers hope for millions who suffer from it worldwide.
These leading healthcare facilities not only provide patients with access to cutting-edge treatments but also serve as vital sources for advancements that can transform lives affected by atherosclerosis. By joining forces through these impactful clinical trials and dedicating resources to innovative research initiatives we come closer every day towards unraveling mysteries behind such diseases which pave way eventual eradication thereof
Which are the best cities for atherosclerosis clinical trials?
When it comes to atherosclerosis clinical trials, several cities in the United States are at the forefront of research. Boston, Massachusetts stands out with 13 active trials exploring treatments such as Olpasiran, Stress Reduction, and IVUS guided PCI. Miami, Florida follows closely behind with 10 ongoing studies focused on interventions like Olezarsen, Obicetrapib, and Metformin XR. New york City also plays a significant role in atherosclerosis research with 9 active trials investigating treatments like IVUS guided PCI and RANGER™ Paclitaxel Coated Balloon. These three cities offer individuals affected by atherosclerosis access to cutting-edge clinical trials that hold promise for advancements in care and improved outcomes.
Which are the top treatments for atherosclerosis being explored in clinical trials?
Atherosclerosis, a condition characterized by the buildup of plaque in the arteries, is being met with innovative treatments in clinical trials. Prominent among these are stress reduction techniques, which have shown promise in two active and two all-time atherosclerosis trials since 2018. Additionally, olezarsen has caught attention for its potential benefits and is currently under investigation in two ongoing trials after first being listed in 2022. Inclisiran has also emerged as an intriguing candidate, with six all-time atherosclerosis trials and two active studies underway following its introduction to the medical scene in 2017. Finally, obicetrapib rounds out this list of top contenders with its inclusion in two current investigations since it was first listed just last year.
What are the most recent clinical trials for atherosclerosis?
Exciting advancements in the field of atherosclerosis research bring hope for improved treatments and outcomes. Recent clinical trials have investigated several interventions targeting this condition. One such trial focuses on tirzepatide, aiming to assess its effectiveness in managing atherosclerosis. Another promising study explores the potential benefits of semaglutide as a treatment option for this disease. Additionally, metformin XR has been evaluated to determine its impact on atherosclerosis progression. Lastly, inclisiran sodium 300mg is being investigated in Phase 3 trials for its potential role in combating this condition. These ongoing studies hold promise for advancing our understanding and management of atherosclerosis, offering new possibilities for patients' well-being.
What atherosclerosis clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of atherosclerosis research. In August 2021, Novo Nordisk A/S concluded a trial investigating the potential of NNC0385-0434 A 15 mg as a treatment option. Mayo Clinic's trial exploring Granulocyte Colony-Stimulating Factor (G-CSF) reached completion in June 2018, shedding light on its effectiveness against this condition. Furthermore, in April 2017, Novartis Pharmaceuticals wrapped up their study evaluating Inclisiran. These trials signify important progress and offer hope for improved interventions to combat atherosclerosis and its associated complications.